We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2268:HKEXWuXi XDC Cayman, Inc. Analysis

Data as of 2026-03-14 - not real-time

HK$54.10

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

WuXi XDC is trading at HK$54.1, well below the analyst median target of HK$84.8, implying roughly a 57% upside. The company delivered 62% YoY revenue growth, an operating margin of 28%, ROE around 20%, and a forward PE of 27.6, indicating strong earnings momentum despite a trailing PE of 46.6.
Technical indicators place the price beneath the 20‑day (≈61) and 50‑day (≈64) SMAs, with RSI at 35 and a bearish MACD, suggesting short‑term pressure but also an oversold condition near the identified support of HK$53.55. Volume is increasing, offering liquidity for a potential bounce.
The newly announced strategic collaboration with Earendil Labs on the WuXiTecan‑2 payload‑linker platform adds a credible growth catalyst in the fast‑growing ADC market. Coupled with a low beta (≈0.35) and a strong cash position versus debt, the fundamentals support a medium‑term rally, while the absence of a dividend means returns rely on capital appreciation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support at HK$53.55
  • Oversold RSI suggesting potential bounce
  • Increasing volume providing liquidity

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong 62% revenue growth and high operating margins
  • Strategic partnership with Earendil Labs expanding ADC pipeline
  • Significant upside to analyst target price (~57%)

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustainable cash generation and low systematic risk (beta 0.35)
  • Long‑term tailwinds in bioconjugate and ADC markets
  • Potential regulatory and China‑specific execution risks

Key Metrics & Analysis

Financial Health

Revenue Growth62.20%
Profit Margin26.08%
P/E Ratio46.6
ROE19.76%
ROA9.04%
Debt/Equity13.96
P/B Ratio7.7
Op. Cash FlowHK$1.5B
Free Cash FlowHK$-332979488
Industry P/E26.2

Technical Analysis

TrendNeutral
RSI35.4
SupportHK$53.55
ResistanceHK$68.10
MA 20HK$61.01
MA 50HK$64.12
MA 200HK$61.18
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueHK$34.80
Target PriceHK$85.42
Upside/Downside57.88%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.35
Volatility52.70%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.